Role of 18F-FDG PET/CT imaging in cardiac and pericardial masses

J Nucl Cardiol. 2022 Jun;29(3):1293-1303. doi: 10.1007/s12350-020-02510-9. Epub 2021 Jan 18.

Abstract

Background: Considering the few reported cardiac masses, PET/CT in the imaging workup of cardiac masses is not well established. This retrospective study analyzed the role of 18F-FDG PET/CT imaging in cardiac/pericardial masses.

Methods and results: Fifty-nine patients with newly diagnosed cardiac/pericardial masses who underwent PET/CT and transthoracic echocardiography (TTE) were recruited. Echocardiographic and PET/CT characteristics were evaluated for predictive value in differentiating malignant and non-malignant lesions using histologic confirmation as the gold standard. The McNemar test was used to test the differences in sensitivity between PET/CT and TTE. 18F-FDG PET/CT had higher sensitivity in determining the malignancy of cardiac/pericardial masses compared to TTE (sensitivity, 96.6% vs 72.4%, P = .039). However, when pericardial masses were excluded from the analysis, the difference in sensitivity between the two was not statistically significant (sensitivity, 95.6% vs 78.3%, P = .219). 18F-FDG PET/CT identified two malignant pericardial masses missed on TTE, changed the diagnostic orientation of TTE in 15 patients, and found seven patients with extracardiac lesions in 29 malignant patients.

Conclusions: PET/CT was an effective additional image modality in patients with suspected malignant cardiac mass for further confirmation and to screen for potential metastasis.

Keywords: 18F-FDG PET/CT imaging; Cardiac tumor; cardiac angiosarcoma; cardiac myxoma; echocardiography.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Fluorodeoxyglucose F18*
  • Heart
  • Humans
  • Positron Emission Tomography Computed Tomography* / methods
  • Positron-Emission Tomography
  • Retrospective Studies

Substances

  • Fluorodeoxyglucose F18